Yenidoğan Sarılıklarına Yaklaşım

Authors

Melek Büyükeren

Synopsis

Neonatal jaundice is a common clinical finding in newborns, observed as yellowing of the skin and conjunctiva when total serum bilirubin exceeds 5 mg/dL. Jaundice is primarily evaluated under two main categories: unconjugated (indirect) and conjugated (direct) hyperbilirubinemia. Unconjugated hyperbilirubinemia, which accounts for the vast majority of cases, develops due to shortened erythrocyte lifespan, insufficient hepatic UGT1A1 conjugation enzyme levels, and increased enterohepatic circulation in newborns. While physiological jaundice, which does not appear within the first 24 hours, usually resolves spontaneously, pathological jaundice starting within the first 24 hours of life, with bilirubin levels rising faster than 0.2 mg/dL per hour or reaching extremely high levels, stems from ABO/Rh incompatibility, G6PDH deficiency, or hereditary disorders such as Crigler-Najjar syndrome. In severe and untreated cases, unconjugated bilirubin can cross the blood-brain barrier, causing acute or chronic bilirubin encephalopathy (kernicterus) and permanent neurological sequelae. Hour-specific bilirubin nomograms based on postnatal age are of vital importance for risk assessment during follow-up and discharge planning. Phototherapy, which converts bilirubin into water-soluble lumirubin, constitutes the first line of treatment. In severe cases with inadequate response or accompanying hemolysis, intravenous immunoglobulin (IVIG) and exchange transfusion are performed. On the other hand, conjugated hyperbilirubinemia is always pathological, originating from biliary atresia, infections, or metabolic diseases. In cases of prolonged jaundice, other underlying pathologies must strictly be excluded before diagnosing breast milk jaundice.

References

Wong RJ, Bhutani VK. Unconjugated hyperbilirubinemia in the newborn: Pathogenesis and etiology. Available at: www.uptodate.com Accessed 05 Dec 2019

Mitra S, Rennie J. Neonatal jaundice: aetiology, diagnosis and treatment. Br J Hosp Med (Lond), 2017; 78 (12): 699-704. Doi: 10.12968/hmed.2017.78.12.699.

Maisels MJ. Jaundice. In Avery GB, Fletcher MA, MacDonald MG (eds). Neonatology: Pathophysiology and Management of the Newborn (5th ed). Philadelphia: JB, Lippincott, 1999: 765-819.

Kaplan M, Muraca M, Hammerman C, et al. Imbalance between production and conjugation of bilirubin: a fundamental concept in the mechanism of neonatal jaundice. Pediatrics. 2002; 110(4):e47. Doi: 10.1542/peds.110.4.e47.

Kaplan M, Wong RJ, Sibley E, et al. Neonatal jaundice and liver disease. In: Martin RJ, Fanaroff AA, Walsh C (eds). Fanaroff and Martin’s Neonatal-Perinatal Medicine. Diseases of the Fetus and Infant (10th ed). Philadelphia:Elsevier Saunders,2015:1617-1673.

Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med. 2001; 344(8):581-590. Doi: 10.1056/NEJM200102223440807.

Çoban A, Türkmen M, Gürsoy T. Türk Neonatoloji Derneği Yenisoğan Sarılıklarında Yaklaşım, İzlem ve Tedavi Rehberi 2014. 1-36.

Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999; 103(1): 6-14. Doi: 10.1542/peds.103.1.6.

Maisels MJ, Bhutani VK, Bogen D, et al. Hyperbilirubinemia in the newborn infant ≥35 weeks gestation: an update with clarification. Pediatrics 2009; 124(4): 1193-1198. Doi: 10.1542/peds. 2009-0329.

Maisels MJ. Use TcB as ascreening tool for jaundiced newborns. AAP News. 2004; 25(1): 9-13.

American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114(1):297-316. Doi: 10.1542/peds.114.1.297.

Pan DH, Rivas Y. Jaundice: Newborn to Age 2 Months. Pediatr Rev. 2017;38(11):499-510. Doi: 10.1542/pir.2015-0132.

Neonatal-Jaundice identification and management in neonates ≥ 32 weeks gestation. NSW Goverment Guideline, GL_2016-027, Available at: http://www. health.nsw.gov.au/policies/. Accessed 17 Nov 2019

National Collaborating Centre for Women’s and Children’s Health. Neonatal jauindice. Londan: RCOG Press, 2010 May.

Sarıcı SÜ. Sarılık. İçinde: Yiğit Ş (ed). Yurdakök Pediatri Kısım 6: Yenidoğan Hastalıkları. Ankara: Güneş Tıp Kitabevleri, 2018:210-224.

Yurdakök M. Phototherapy in the newborn: what’s new? J Pediatr Neonat Individual Med. 2015;4(2):e040255. doi: 10.7363/040255.

Woodgate P, Jardine LA. Neonatal jaundice. BMJ Clin Evid. 2011;2011:0319.

Blanchette VS, Zipursky A. Assessment of anemia in newborn infants. Clin Perinatol. 1984;11(2):489-510.

Kaplan M, Wong RJ, Stevenson DK. Hemolysis and Glucose-6-Phosphate Dehydrogenase Deficiency-Related Neonatal Hyperbilirubinemia. Neonatology. 2018;114(3):223-225. Doi: 10.1159/000489820.

Frank JE. Diagnosis and management of G6PD deficiency. Am Fam Physician. 2005; 72(7):1277-1282.

Skierka JM, Kotzer KE, Lagerstedt SA, et al. UGT1A1 genetic analysis as a diagnostic aid for individuals with unconjugated hyperbilirubinemia. J Pediatr. 2013; 162(6):1146-1152. Doi: 10.1016/j.jpeds.2012.11.042.

Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333(18):1171-1175. Doi: 10.1056/NEJM199511023331802.

Akaba K, Kimura T, Sasaki A, et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int. 1998;46(1):21-26. Doi: 10.1080/ 15216549800203512.

Kadakol A, Sappal BS, Ghosh SS, et al. Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus. J Med Genet. 2001; 38(4):244-249. Doi: 10.1136/jmg.38.4.244.

Watchko JF. Vigintiphobia revisited. Pediatrics 2005; 115(6):1747-1753. Doi: 10.1542/peds. 2004-1748.

Wainer S, Rabi Y, Parmar SM, et al. Impact of skin tone on the performance of a transcutaneous jaundice meter. Acta Paediatr. 2009;98(12):1909-1915. Doi: 10.1111/j.1651-2227.2009. 01497.x.

Casnocha Lucanova L, Matasova K, Zibolen M, et al. Accuracy of transcutaneous bilirubin measurement in newborns after phototherapy. J Perinatol. 2016;36(10):858-861. Doi: 10.1038/ jp.2016.91.

Rathore S, Sharashchandra R. A critical review on neonatal hyperbilirubinemia-an ayurvedic perspective. J Ayurveda Integr Med. 2020;11(2):190-196. Doi: 10.1016/j.jaim.2018.08.006

Helal NF, Ghany EA, Abuelhamd WA, et al. Characteristics and outcome of newborn admitted with acute bilirubin encephalopathy to a tertiary neonatal intensive care unit. World J Pediatr. 2019;15(1):42-48. Doi: 10.1007/s12519-018-0200-4.

Wisnowski JL, Panigrahy A, Painter MJ, et al. Magnetic resonance imaging of bilirubin encephalopathy: current limitations and future promise. Semin Perinatol. 2014;38(7):422-428. Doi: 10.1053/j.semperi.2014.08.005.

Karimzadeh P, Fallahi M, Kazemian M, et al. Bilirubin Induced Encephalopathy. Iran J Child Neurol. 2020;14(1):7-19.

Ribeiro BN, Lima GD, Ventura N, et al. Chronic kernicterus: magnetic resonance imaging findings. Radiol Bras. 2016 ;49(6):407-408. Doi: 10.1590/0100-3984.2015.0190.

Usman F, Diala UM, Shapiro SM, et al. Acute bilirubin encephalopathy and its progression to kernicterus: current perspectives. Research and Reports in Neonatology. 2018;8:33-44. Doi: 10.2147/RRN.S125758

Hulzebos CV, Dijk PH. Bilirubin–albumin binding, bilirubin/albumin ratios, and free bilirubin levels: Where do we stand? Semin Perinatol. 2014;38(7):412-421. Doi: 10.1053/j.semperi. 2014.08.004.

Amin SB. Bilirubin binding capacity in the preterm neonate. Clin Perinatol. 2016;43(2):241-257. Doi: 10.1016/j.clp.2016.01.003.

Shapiro SM. Definition of the clinical spectrum of kernicterus and bilirubin induced neurologic dysfunction (BIND). J Perinatol. 2005; 25: 54-59. Doi: 10.1038/sj.jp.7211157.

Bhutani VK, Johnson-Hamerman L. The clinical syndrome of bilirubin-induced neurologic dysfunction. Semin Fetal Neonatal Med. 2015 Feb;20(1):6-13. Doi: 10.1016/j.siny.2014.12. 008.

Shapiro SM. Chronic bilirubin encephalopathy: diagnosis and outcome. Semin Fetal Neonatal Med. 2010;15(3):157-163. Doi: 10.1016/j.siny.2009.12.004.

Nam GS, Kwak SH, Bae SH, et al. Hyperbilirubinemia and Follow-up Auditory Brainstem Responses in Preterm Infants. Clin Exp Otorhinolaryngol 2019;12(2):163-168. Doi: 10.21053/ ceo.2018.00899.

Woodgate P, Jardine LA. Neonatal jaundice: phototherapy. BMJ Clin Evid. 2015;2015:0319.

Hansen TWR, Maisels MJ, Ebbesen F, et al. Sixty years of phototherapy for neonatal jaundice - from serendipitous observation to standardized treatment and rescue for millions. J Perinatol. 2020; 40(2):180-193. Doi: 10.1038/s41372-019-0439-1.

Newman TB, Kuzniewicz MW, Liljestrand P, et al. Numbers needed to treat with phototherapy according to American Academy of Pediatrics guidelines. Pediatrics. 2009; 123 (5):1352-1359. Doi: 10.1542/peds.2008-1635.

Ennever JF, Costarino AT, Polin RA, et al. Rapid clearance of a structural isomer of bilirubin during phototherapy. J Clin Invest. 1987; 79 (6):1674-1678. Doi: 10.1172/JCI113006.

Kumar P, Chawla D, Deorari A. Light-emitting diode phototherapy for unconjugated hyperbilirubinaemia in neonates. Cochrane Database Syst Rev. 2011; 2011(12):CD007969. Doi: 10.1002/14651858.CD007969.pub2.

Tridente A, De Luca D. Efficacy of light-emitting diode versus other light sources for treatment of neonatal hyperbilirubinemia: a systematic review and meta-analysis. Acta Paediatr. 2012; 101(5):458-465. Doi: 10.1111/j.1651-2227.2011.02561.x.

Bhutani VK, Committee on Fetus and Newborn, American Academy of Pediatrics. Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2011; 128(4):e1046-e1052. Doi: 10.1542/peds.2011-1494.

Slusher TM, Olusanya BO, Vreman HJ, et al. A Randomized Trial of Phototherapy with Filtered Sunlight in African Neonates. N Engl J Med. 2015; 373(12):1115-1124. Doi: 10.1056/ NEJMoa1501074.

Chang PW, Waite WM. Evaluation of Home Phototherapy for Neonatal Hyperbilirubinemia. J Pediatr 2020; 220:80-85. Doi: 10.1016/j.jpeds.2020.01.004.

Le TN, Reese J. Bronze Baby Syndrome. J Pediatr. 2017 Sep;188:301-301.e1. Doi: 10.1016/ j.jpeds.2017.05.005.

Türk Neonatoloji Derneği Tanı ve Tedavi Protokolleri No. 1. Türk Neonatoloji Derneği Bülteni. Sayı: 6 – Güz 2002.

Jackson JC. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics. 1997;99(5):E7. Doi: 10.1542/peds.99.5.e7.

Yurdakök M, Yiğit Ş, Çelik HT. Hiperbilirubinemi. İçinde: Yenidoğan Bakımında Hacettepe Uygulamaları. Ankara: Güneş Tıp Kitabevleri, 2019:166-176.

Grunebaum E, Amir J, Merlob P, et al. Breast mild jaundice: natural history, familial incidence and late neurodevelopmental outcome of the infant. Eur J Pediatr. 1991; 150(4):267-270. Doi: 10.1007/BF01955528.

Preer GL, Philipp BL. Understanding and managing breast milk jaundice. Arch Dis Child Fetal Neonatal Ed. 2011; 96(6):F461-F466. Doi: 10.1136/adc.2010.184416.

Gourley GR, Arend RA. beta-Glucuronidase and hyperbilirubinaemia in breast-fed and formula-fed babies. Lancet. 1986; 1(8482):644-646. Doi: 10.1016/s0140-6736(86)91724-1.

Ansong-Assoku B, Ankola PA. Neonatal Jaundice. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan.

Takamizawa S, Zaima A, Muraji T, et al. Can biliary atresia be diagnosed by ultrasonography alone? J Pediatr Surg. 2007;42(12):2093-2096. Doi: 10.1016/j.jpedsurg.2007.08.032.

Pages

175-196

Published

January 4, 2022

License

License